TradingKey

• Circle Internet Group stock rose on analyst upgrade and partnership. • OSL Group partnership expands global USDC access and trading. • Company shows growth in stablecoin market and technological innovation.

• CoreWeave closed a $1 billion Senior Notes offering for corporate purposes. • Secured multi-billion dollar AI cloud contracts with Meta, Anthropic, and Jane Street. • Analysts maintain positive ratings with increased price targets and institutional buying.

• Cameco secured a $2.6 billion long-term uranium supply agreement with India. • Analysts increased earnings estimates and issued "Outperform" ratings for Cameco. • Uranium market faces supply deficit, policy support, and rising energy demand.

• Coinbase stock rebounded amid positive cryptocurrency market sentiment. • Institutional buying pressure, partnerships, and new listings boosted confidence. • Analysts maintain positive ratings and price targets for Coinbase.

• MicroStrategy acquired 34,164 Bitcoin for $2.54 billion. • Capital Group acquired 4.32 million MSTR shares for $747 million. • Analyst price targets were raised for MicroStrategy.

• TE Connectivity exceeded earnings and revenue estimates, raised dividend. • Declines in Transportation and Medical segments impacted organic sales. • Investors reacted negatively, possibly due to prior appreciation and insider selling.

• BHP affirmed copper guidance, expects upper half of range. • Iron ore output surpassed expectations; supply dispute resolved. • Copper prices rose; supported by restocking and risk sentiment.

• Forrester study shows 264% ROI for CrowdStrike Falcon Cloud Security. • CrowdStrike expands Cloud Detection and Response to Google Cloud. • KeyBanc upgrades CrowdStrike stock to "Buy" with new price target.

• FCX stock volatility driven by earnings, commodity outlook, and analyst revisions. • Copper and gold market strength supports positive sentiment for FCX. • Grasberg mine restart and dividend signal boost investor confidence.

• Marvell Technology in talks with Google for custom AI chip development. • Analysts raise Marvell price targets on data center and AI optimism. • Marvell reports strong fiscal 2026 data center growth driven by AI.

• Boston Scientific reported Q1 2026 net sales of $5.203 billion, up 11.6%. • Adjusted EPS was $0.80, exceeding analyst expectations of $0.79. • Full-year 2026 guidance was revised downwards for sales and adjusted EPS.

• TSM reported Q1 2026 revenue of $35.9 billion, driven by AI chip demand. • TSM projects over 30% revenue growth in 2026, fueled by AI demand. • Analysts maintain "Buy" ratings with raised price targets for TSM.

• Lockheed Martin's share price fell due to earnings concerns. • Peru postponed a multi-billion dollar F-16 fighter jet acquisition. • Analysts lowered EPS and revenue estimates before earnings report.

• Land & Buildings criticized Welltower's executive program. • A peer REIT's IPO missed targets, signaling caution. • Welltower faces scrutiny despite positive market/analyst ratings.

• Adobe announced a $25 billion stock repurchase program. • New AI platforms and tools were unveiled at the annual Summit. • Adobe reported record Q1 FY26 revenue of $6.40 billion.

• VRT's stock declined due to Q1 earnings report and guidance. • Q2 revenue guidance fell short of elevated investor expectations. • EMEA region sales showed significant year-over-year decline.

• Sandisk benefits from AI demand and NAND memory market strength. • Analysts upgraded forecasts, anticipating revenue and earnings growth. • Inclusion in Nasdaq-100 Index boosts stock appeal and buying pressure.

• Broadcom and Google Cloud expand collaboration for network insights. • Broadcom reported strong Q1 FY2026 AI revenue growth exceeding forecasts. • Analysts maintain a positive outlook with a consensus "Buy" rating.

• RTX reported strong Q1 2026 earnings exceeding estimates. • Company raised full-year guidance but revenue midpoint missed projections. • Analysts cite GTF platform, headwinds, and reduced price target.

• Danaher beat first-quarter earnings expectations but missed revenue estimates. • Bioprocessing strength offset weakness in Cepheid and diagnostics. • Analysts lowered price targets despite a raised full-year earnings forecast.